Review article · 2017 · Open access
Engineering Natural Killer Cells for Cancer Immunotherapy
Molecular Therapy, 25(8), 1769–1781 · Published 28 June 2017 · DOI 10.1016/j.ymthe.2017.06.012
In brief
“Engineering Natural Killer Cells for Cancer Immunotherapy” is a 2017 review article by Katayoun Rezvani and 3 co-authors, published in Molecular Therapy. OpenAlex counts 474 citations as of 21 November 2026, which puts it in the top 2% of works published in 2017 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Molecular Therapy.
- Citations
- 474
- Most cited in
- 2021 (83)
- Field-weighted impact
- 4.92
- References
- 144
- Authors
- 4
Abstract
The past several years have seen tremendous advances in the engineering of immune effector cells as therapy for cancer. While chimeric antigen receptors (CARs) have been used extensively to redirect the specificity of autologous T cells against hematological malignancies with striking clinical results, studies of CAR-modified natural killer (NK) cells have been largely preclinical. In this review, we focus on recent advances in NK cell engineering, particularly on preclinical evidence suggesting that NK cells may be as effective as T cells in recognizing and killing targets after genetic modification. We will discuss strategies to introduce CARs into both primary NK cells and NK cell lines in an effort to provide antigen specificity, the challenges of manufacturing engineered NK cells, and evidence supporting the effectiveness of this approach from preclinical and early-phase clinical studies using CAR-engineered NK cells. CAR-NK cells hold great promise as a novel cellular immunotherapy against refractory malignancies. Notably, NK cells can provide an "off-the-shelf" product, eliminating the need for a personalized and patient-specific product that plagues current CAR-T cell therapies. The ability to more potently direct NK cell-mediated cytotoxicity against refractory tumors through the expression of CAR is likely to contribute to the recent paradigm shift in cancer treatment.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Rezvani, K., Rouce, R. H., Liu, E., & Shpall, E. J. (2017). Engineering Natural Killer Cells for Cancer Immunotherapy. Molecular Therapy, 25(8), 1769–1781. https://doi.org/10.1016/j.ymthe.2017.06.012
MLA 9
Rezvani, Katayoun, et al. “Engineering Natural Killer Cells for Cancer Immunotherapy.” Molecular Therapy, vol. 25, no. 8, 2017, pp. 1769–1781. https://doi.org/10.1016/j.ymthe.2017.06.012.
Chicago
Rezvani, Katayoun, Rayne Helen Rouce, Enli Liu, and Elizabeth J. Shpall. 2017. “Engineering Natural Killer Cells for Cancer Immunotherapy.” Molecular Therapy 25 (8): 1769–1781. https://doi.org/10.1016/j.ymthe.2017.06.012.
Harvard
Rezvani, K. et al. (2017) ‘Engineering Natural Killer Cells for Cancer Immunotherapy’, Molecular Therapy, 25(8), pp. 1769–1781. doi:10.1016/j.ymthe.2017.06.012.
IEEE
K. Rezvani, R. H. Rouce, E. Liu, and E. J. Shpall, “Engineering Natural Killer Cells for Cancer Immunotherapy,” Molecular Therapy, vol. 25, no. 8, pp. 1769–1781, 2017, doi: 10.1016/j.ymthe.2017.06.012.
BibTeX
@article{rezvani2017engineering,
title = {{Engineering Natural Killer Cells for Cancer Immunotherapy}},
author = {Rezvani, Katayoun and Rouce, Rayne Helen and Liu, Enli and Shpall, Elizabeth J.},
journal = {Molecular Therapy},
year = {2017},
volume = {25},
number = {8},
pages = {1769--1781},
doi = {10.1016/j.ymthe.2017.06.012},
url = {https://doi.org/10.1016/j.ymthe.2017.06.012}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 7 | |
| 2018 | 30 | |
| 2019 | 61 | |
| 2020 | 66 | |
| 2021 | 83 | |
| 2022 | 55 | |
| 2023 | 48 | |
| 2024 | 45 | |
| 2025 | 52 | |
| 2026 | 27 |
Its field-weighted citation impact is 4.92: it has been cited 4.92 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- natural killer cells
- CAR-NK cells
- chimeric antigen receptor
- NK cell engineering
- cellular immunotherapy
- off-the-shelf cell products
- NK cell cytotoxicity
- NK cell lines
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Rezvani, K., Rouce, R. H., Liu, E., & Shpall, E. J. (2017). Engineering Natural Killer Cells for Cancer Immunotherapy. Molecular Therapy, 25(8), 1769–1781. https://doi.org/10.1016/j.ymthe.2017.06.012
How many times has this paper been cited?
474 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Molecular Therapy: sign in and open the PDF from this page.
Who wrote this paper?
Katayoun Rezvani, Rayne Helen Rouce, Enli Liu, Elizabeth J. Shpall.
What is the DOI of this paper?
10.1016/j.ymthe.2017.06.012, permanently at https://doi.org/10.1016/j.ymthe.2017.06.012. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.